Sonia Tabacova

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment
    Sonia Tabacova
    National Center for Toxicological Research, US Food and Drug Administration, Center for Drug Evaluation and Research, DNDP, HFD 120, 5600 Fishers Lane, Rockville, MD 20857, USA
    Pharmacoepidemiol Drug Saf 12:633-46. 2003
  2. ncbi Atenolol developmental toxicity: animal-to-human comparisons
    Sonia Tabacova
    Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20857, USA
    Birth Defects Res A Clin Mol Teratol 67:181-92. 2003
  3. ncbi Mode of action: angiotensin-converting enzyme inhibition--developmental effects associated with exposure to ACE inhibitors
    Sonia Tabacova
    US Food and Drug Administration, Rockville, Maryland 20852, USA
    Crit Rev Toxicol 35:747-55. 2005
  4. ncbi NTP Center for the Evaluation of Risks to Human Reproduction: phthalates expert panel report on the reproductive and developmental toxicity of butyl benzyl phthalate
    Robert Kavlock
    National Health and Environmental Effects Research Laboratory, USEPA, Research Triangle Park, NC, USA
    Reprod Toxicol 16:453-87. 2002
  5. ncbi Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data
    Jennifer Seed
    US Environmental Protection Agency, Washington, DC, USA
    Crit Rev Toxicol 35:664-72. 2005

Collaborators

Detail Information

Publications5

  1. ncbi Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment
    Sonia Tabacova
    National Center for Toxicological Research, US Food and Drug Administration, Center for Drug Evaluation and Research, DNDP, HFD 120, 5600 Fishers Lane, Rockville, MD 20857, USA
    Pharmacoepidemiol Drug Saf 12:633-46. 2003
    ..However, no analytical studies on the relationship between the adverse outcomes and enalapril gestational exposures are available...
  2. ncbi Atenolol developmental toxicity: animal-to-human comparisons
    Sonia Tabacova
    Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20857, USA
    Birth Defects Res A Clin Mol Teratol 67:181-92. 2003
    ..We evaluate published human and animal evidence of atenolol developmental toxicity and compare the manifestations in humans and in routinely-used animal models...
  3. ncbi Mode of action: angiotensin-converting enzyme inhibition--developmental effects associated with exposure to ACE inhibitors
    Sonia Tabacova
    US Food and Drug Administration, Rockville, Maryland 20852, USA
    Crit Rev Toxicol 35:747-55. 2005
    ....
  4. ncbi NTP Center for the Evaluation of Risks to Human Reproduction: phthalates expert panel report on the reproductive and developmental toxicity of butyl benzyl phthalate
    Robert Kavlock
    National Health and Environmental Effects Research Laboratory, USEPA, Research Triangle Park, NC, USA
    Reprod Toxicol 16:453-87. 2002
  5. ncbi Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data
    Jennifer Seed
    US Environmental Protection Agency, Washington, DC, USA
    Crit Rev Toxicol 35:664-72. 2005
    ....